A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients

Psychopharmacology Bulletin

Volumn 32, Issue 3, 1996, Pages 335-342

  Wilcox, Charles S ^a,b,c   Ferguson, James M ^d   Dale, Jacqueline L ^a,b,c   Heiser, Jon F ^a,b,c  

^a Pharmacology Research Institute   (United States)

^b Pharmacology Research Institute   (United States)

^c Pharmacology Research Institute   (United States)

^d Pharmacology Research Corporation   (United States)

Author keywords

depression; gepirone ER; noradrenergic; serotonergic

Indexed keywords

GEPIRONE;

ABDOMINAL CRAMP; ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TRANQUILIZING ACTIVITY; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES;

EID: 0029907140     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3d ed., revised. Washington, DC: The Association, 1987.
2. Apter, JT. Frontiers in biological psychiatry: New drug development. New Jersey Medicine 90(2):144-146, 1993.
3. Bech, P, and Coppen, A, eds. Psychometric developments of the Hamilton scales: The spectrum of depression, dysthymia and anxiety. The Hamilton Scales: Psychopharmacology, Series 9. Berlin, Springer-Verlag, 1990. pp.72-79.
4. Cohn, JB; Pyke, RE; and Wilcox, CS. Adinazolam mesylate and placebo in depressed outpatients: A 6-week, double-blind comparison. J. Clin. Psychiatry 49(4):142-147, 1988.
5. Cohn, JB, and Wilcox, CS. Paroxetine in major depression: A double-blind trial with imipramine and placebo. J. Clin. Psychiatry 53(Suppl. 2):52-56, 1992.
6. Cohn, JB; Wilcox, CS; and Goodman, LI. Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. Clin. Ther. 15(1):114-126, 1993.
7. Darcourt, G; Kramer, SJ; and Fabre, LF. A multicenter double-blind placebo controlled trial of gepirone and bromazepam in the treatment of anxious outpatients. Unpublished report, data on file at Fabre-Kramer Pharmaceuticals, Inc., Houston, TX, 1995.
8. Department of Health, Education and Welfare. Guidelines for the Clinical Evaluation of Antidepressant Drugs. DHEW Pub. No. (FDA), Rockville, Maryland. pp. 77-3042, 1977.
9. Eison, AS. Azapirones: History of development. J. Clin. Psychopharmacol. 10(3):2S-5S, 1990.
10. Fabre, LF, and Kramer, SJ. Gepirone-ER bioequivalency with gepirone-IR. Unpublished report, data on file at Fabre-Kramer Pharmaceuticals, Inc., Houston, TX, 1994.
11. Fitton, A, and Benfield, P. Gepirone in depression and anxiety disorders: An initial appraisal of its clinical potential. CNS Drugs 1(5):388-398, 1994.
12. Guy, W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976. pp. 218-222.
13. Hamilton, M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32:50-55, 1959.
14. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
15. Harto, NE; Branconnier, RJ; Spera, KF; and Dessain, EC. Clinical profile of gepirone, a nonbenzodiazepine anxiolytic. Psychopharmacol. Bull. 24:154-160, 1988.
16. Jenkins, SW; Robinson, DS; Fabre, LF; Andary, JJ; Messina, ME; and Reich, LA. Gepirone in the treatment of major depression. J. Clin. Psychopharmacol. 10(Suppl. 3):77S-85S, 1990.
17. Linden, RD; Wilcox, CS; Heiser, JF; Cavanaugh, E; and Wisselink, PG. Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacol. Bull. 30(2):151-156, 1994.
18. McGrath, PJ; Stewart, JW; Quitkin, FM; Wager, S; Jenkins, SW; Archibald, DG; Stringfellow, JC; and Robinson, DS. Gepirone treatment of atypical depression: Preliminary evidence of serotonergic involvement. J. Clin. Psychopharmacol. 14(5):347-352, 1994.
19. Montgomery, SA, and Åsberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134:382-389, 1979.
20. Pecknold, JC; Luther, L; Scott-Fleury, MH; and Jenkins, S. Gepirone and the treatment of panic disorder An open study. J. Clin. Psychopharmacol. 13(2):145-149, 1993.
21. Pinder, RM. Mianserin: Pharmacological and clinical correlates. Nordisk Psykiatrisk Tidsskrift 45(Suppl. 24): 13-26, 1991.
22. SAS Institute Inc. SAS Users Guide. Version 5.18. Cary, NC: SAS Institute Inc.
23. Stahl, S. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol. Bull. 30(1):39-43, 1994.
24. Walker, PW; Cole, JO; Gardner, EA; Hughes, AR; Johnston, JA; Batey, SR; and Lineberry, CG. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J. Clin. Psychiatry 54:459-465, 1993.
25. Wilcox, CS; Cohn, JB; Katz, BB; Mijares, CP; Guarino, JJ; Panagides, J; and DeFrancisco, DF. A double-blind, placebocontrolled study comparing mianserin and amitripytline in moderately depressed outpatients. Inter. Clin. Psychopharmacol. 9:271-279, 1994.
26. Wilcox, CS; Hamilton, M; Cohn, JB; and Addis, B. The Hamilton Depression Rating Scale: A training film for the assessment of depressed patients. University of California at Los Angeles: Behavioral Sciences Media Laboratory. April 1987.
27. 2 receptor-mediated behavior by continuous gepirone treatment. Life Sci. 49(24): 1777-1785, 1991.